BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15638856)

  • 21. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
    Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
    Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia.
    Benites BD; Traina F; Duarte Ada S; Lorand-Metze IG; Costa FF; Saad ST
    Eur J Haematol; 2010 Jun; 84(6):525-30. PubMed ID: 20345447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
    Minetto P; Guolo F; Clavio M; De Astis E; Colombo N; Grasso R; Fugazza G; Sessarego M; Lemoli RM; Gobbi M; Miglino M
    Leuk Res; 2015 Aug; 39(8):866-73. PubMed ID: 26012361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.
    Appelbaum FR; Anderson J
    Leukemia; 1998 Sep; 12 Suppl 1():S25-9. PubMed ID: 9777891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes.
    Luo SS; Ogata K; Yokose N; Kato T; Dan K
    Stem Cells; 2000; 18(2):112-9. PubMed ID: 10742383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway.
    Ellis MH; Baraf L; Shaish A; Har-Zahav A; Harats D; Ashur-Fabian O
    Exp Hematol; 2012 Jul; 40(7):540-547.e1. PubMed ID: 22381680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
    Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome.
    Poloni A; Serrani F; Berardinelli E; Maurizi G; Mariani M; Costantini B; Trappolini S; Mancini S; Olivieri A; Leoni P
    Leuk Res; 2013 Nov; 37(11):1538-44. PubMed ID: 24095110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.
    Huang TC; Ko BS; Tang JL; Hsu C; Chen CY; Tsay W; Huang SY; Yao M; Chen YC; Shen MC; Wang CH; Tien HF
    Leukemia; 2008 Mar; 22(3):544-50. PubMed ID: 18094713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
    Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
    Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXXC4 mRNA levels are associated with clinicopathological parameters and survival of myelodysplastic syndrome patients.
    Li S; Fan R; Zhao XL; Wang XQ
    Leuk Res; 2014 Sep; 38(9):1072-8. PubMed ID: 25085016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
    Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
    Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Rigolin GM; Rosti V; Bonetti E; Travaglino E; Boveri E; Gallì A; Boggi S; Ciccone M; Pramparo T; Mazzini G; Invernizzi R; Lazzarino M; Cazzola M
    Leukemia; 2008 Mar; 22(3):530-7. PubMed ID: 18094717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
    Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
    Wang H; Wang XQ; Xu XP; Lin GW
    Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.